The involvement of nutraceuticals to sustainable heathcare in Europe in the context of major depressive disorder (MDD), Dr. Nahlaa A. Khalifa and Dr. Elham A. Aljaaly
Dr. Nahlaa A. Khalifa and Dr. Elham A. Aljaaly
Clinical Nutrition Department,Faculty of Applied Medical Sciences,King Abdulaziz University, Saudi Arabia
Purpose: Study evidence-based records on some effective nutraceuticals to be involve in Europe in Major Depression Disorder (MDD) management. Represent nutraceuticals anti-depressant properties to achieve the European health policy targets ‘Investing in Health’ and upkeep sustainable healthcare systems.
Methodology: Gaining literature by searching MEDLINE (PubMed), Google Scholar, PsychINFO and Quertile databases
and retrieving relevant published articles in the peer-reviewed journals.
Findings: Results provided evidence of a range of nutraceuticals, which are of potential benefits in management of depression. Studies support the anti-depressant properties of S-Adenosyl Methionine (SAMe), Folnic acid, 5-hydroxytryptophan (5-HTP) and omega-3 fatty acids. The results might give evidence for innovative adjunctive neurobiological line for managing and treating depression in Europe.
Practical implications: Randomised controlled trials and evaluation process continue to provide evidence for the nutraceuticals use for depression.
Social implications: Nutraceuticals emphasise the Person-focused Medicine, which offers a psychophysical balance to the individual.
Originality/value: Nutraceuticals have specific antidepressant properties that found to be of benefit in psychiatric population and reduce the pharmacotherapeutic side effects.
Keywords: Complementary and Alternative Medicine, CAM, Nutraceuticals, Depression, Anti-depressant, S-Adenosyl Methionine, SAMe, Folic Acid, 5-hydroxytryptophan, 5-HTP, Omega-3, Sustainability, Europe.
